SEMINARS IN ARTHRITIS AND RHEUMATISM

metrics 2024

Unveiling the latest in arthritis and pain medicine.

Introduction

SEMINARS IN ARTHRITIS AND RHEUMATISM, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of rheumatology and pain medicine. With an impressive impact factor and recognized as a Q1 journal in both its categories, it ranks #8 in Anesthesiology and Pain Medicine and #11 in Rheumatology based on the latest Scopus data, placing it within the top echelons of academic research. Established in 1971, this esteemed publication offers a comprehensive platform for researchers and practitioners to disseminate and engage with cutting-edge studies that advance the understanding and treatment of arthritis and related conditions. With its robust editorial process and focus on high-quality, peer-reviewed articles, the journal not only contributes to scientific knowledge but also serves as an essential resource for professionals and students seeking contemporary insights into effective management strategies and emerging therapies in the rheumatologic field. Although it does not offer open access, its subscription model ensures a wide distribution among academic and clinical institutions, reinforcing its significance in the research community.

Metrics 2024

SCIMAGO Journal Rank1.72
Journal Impact Factor4.60
Journal Impact Factor (5 years)4.90
H-Index134
Journal IF Without Self4.60
Eigen Factor0.01
Normal Eigen Factor2.50
Influence1.66
Immediacy Index0.60
Cited Half Life7.00
Citing Half Life7.30
JCI1.20
Total Documents2422
WOS Total Citations9440
SCIMAGO Total Citations30822
SCIMAGO SELF Citations765
Scopus Journal Rank1.72
Cites / Document (2 Years)4.28
Cites / Document (3 Years)4.53
Cites / Document (4 Years)4.93

Metrics History

Rank 2024

Scopus

Anesthesiology and Pain Medicine in Medicine
Rank #8/136
Percentile 94.12
Quartile Q1
Rheumatology in Medicine
Rank #11/73
Percentile 84.93
Quartile Q1

IF (Web Of Science)

RHEUMATOLOGY
Rank 10/57
Percentile 83.30
Quartile Q1

JCI (Web Of Science)

RHEUMATOLOGY
Rank 11/57
Percentile 80.70
Quartile Q1

Quartile History

Similar Journals

Reumatologia

Bridging academia and practice in Immunology and Allergy.
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 0034-6233Frequency: 6 issues/year

Reumatologia is a dedicated open-access journal published by TERMEDIA PUBLISHING HOUSE LTD that has been serving the global scientific community since 2005. The journal focuses on the fields of Rheumatology, Immunology, and Allergy, providing a rich platform for researchers and practitioners to share innovative findings, clinical insights, and methodologies. With its roots tracing back to the early 1960s and a steady convergence of quality content through 2024, Reumatologia has secured a place in the academic landscape, currently holding a Q4 rating in Immunology and a Q3 rating in both Immunology and Allergy and Rheumatology categories for 2023. While the journal ranks #42 out of 73 in the Medicine - Rheumatology category, its open-access model ensures that research is widely disseminated, enhancing visibility and accessibility to vital knowledge that shapes therapeutic practices. Located in Poznan, Poland, Reumatologia remains a pivotal source of credible research, fostering collaboration among academics, healthcare professionals, and students internationally.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Fostering Insights for Enhanced Patient Outcomes
Publisher: TAYLOR & FRANCIS LTDISSN: 0300-9742Frequency: 6 issues/year

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.

Reumatologia Clinica

Elevating the standard of care in rheumatology.
Publisher: ELSEVIER ESPANA SLUISSN: 1699-258XFrequency: 6 issues/year

Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.

RMD Open

Leading the way in open-access rheumatology research.
Publisher: BMJ PUBLISHING GROUPISSN: 2056-5933Frequency: 2 issues/year

RMD Open, published by the BMJ Publishing Group, is a leading open-access journal that has made significant contributions to the fields of Immunology, Immunology and Allergy, and Rheumatology since its inception in 2015. With an impressive Q1 ranking in these categories for 2023, the journal has established itself as an essential platform for the dissemination of high-quality research, case studies, and reviews that advance understanding and treatment strategies in these critical areas of health. As an open-access publication, RMD Open ensures that its content is freely accessible to a global audience, promoting collaboration and knowledge sharing among researchers, clinicians, and students. Based in the United Kingdom at the British Medical Association House, RMD Open is not only dedicated to improving patient care but also to fostering innovative research and discussions in the rapidly evolving landscape of rheumatic diseases.

Egyptian Rheumatologist

Empowering research, transforming care.
Publisher: ELSEVIERISSN: 1110-1164Frequency: 4 issues/year

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

Journal of Rheumatic Diseases

Leading the way in innovative therapeutic strategies and diagnostics.
Publisher: KOREAN COLL RHEUMATOLOGYISSN: 2093-940XFrequency: 4 issues/year

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

Modern Rheumatology

Advancing the Future of Rheumatology
Publisher: OXFORD UNIV PRESSISSN: 1439-7595Frequency: 6 issues/year

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Current Rheumatology Reports

Leading the way in rheumatological discoveries.
Publisher: SPRINGERISSN: 1523-3774Frequency: 12 issues/year

Current Rheumatology Reports is a premier journal dedicated to advancing the field of rheumatology, published by Springer. With an esteemed Q1 category ranking in Rheumatology as of 2023 and a remarkable Scopus rank of 6 out of 73, this journal stands at the forefront of research dissemination, boasting an impressive percentile ranking in the 92nd. Since its inception in 1999, Current Rheumatology Reports has provided a critical platform for the latest findings in rheumatological diseases, treatment strategies, and clinical practices. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures high-quality publications that are essential for researchers, clinicians, and students alike. By keeping the community informed of key developments, this journal plays a vital role in shaping contemporary rheumatological research and practice, thereby facilitating the advancement of patient care worldwide.

JOURNAL OF RHEUMATOLOGY

Your Essential Resource for Cutting-Edge Rheumatological Research
Publisher: J RHEUMATOL PUBL COISSN: 0315-162XFrequency: 12 issues/year

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

International Journal of Rheumatology

Advancing knowledge in rheumatology and immunology.
Publisher: HINDAWI LTDISSN: 1687-9260Frequency: 1 issue/year

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.